Roxadustat

Roxadustat is an oral anemia drug discussed by biohackers for endurance and clearer thinking. The most useful training log starts with no blood-count change after two weeks, then reports a later hematocrit rise; another person describes better cardio and clarity. These accounts do not establish a dependable performance or cognitive benefit.

What Roxadustat is

• FG-4592 and Evrenzo refer to the same active drug. Roxadustat is a small molecule, not a peptide or a SARM. FG-4592 is its development code; Evrenzo is a prescription tablet brand. A research powder carrying the name is not thereby verified as equivalent to the licensed medicine. Official context Official context Official context Community · Reddit
• The attraction is an oxygen-response pathway. It inhibits HIF prolyl hydroxylase, helping activate the body’s low-oxygen response and production of erythropoietin, the signal for making red blood cells. That explains why discussions connect it to altitude and endurance. It does not make a self-experiment equivalent to altitude training. Official context Personal report
• Blood measures are not performance scores. Hematocrit is the percentage of blood occupied by red cells; hemoglobin is their oxygen-carrying protein. Hydration and altitude can affect hematocrit. These distinctions matter when reading an athlete’s blood log alongside a patient’s hemoglobin results. Official context Official context

Benefits people report and seek

• Endurance reports include both disappointment and later enthusiasm. The training-log author initially suspected placebo, later described Roxa as useful for VO2 and racing blocks, and reported changing blood measurements. No controlled race result or measured VO2 improvement was supplied. The account supports a reported experience, not a predictable gain. Personal report
• Clearer thinking appears in one brief favorable report. A separate commenter described better cardio and clearer thinking after two months. There is no cognitive test, onset diary or baseline comparison. The same comment is quoted elsewhere, which can make the evidence look broader than it is. Personal report Community · Reddit
• Treating anemia answers a different question. EMA’s clinical evidence concerns adults with symptomatic anemia from chronic kidney disease. Improving hemoglobin in that population does not establish an endurance or nootropic benefit in someone without that condition. Official context

Comparisons that change the meaning

• EPO is the closest pathway comparison. Injected erythropoietin directly stimulates red-cell production; roxadustat acts through oxygen-response signaling to encourage the body’s own production. Oral administration does not remove blood-related risks. The patient account involving earlier EPO and later roxadustat is a treatment history, not proof one is safer. Official context Personal report
• Cardarine is a training comparison in the actual log. The author preferred Cardarine for returning to longer base-training days but said it dulled top-end performance, while favoring Roxa for racing blocks. This is one person’s comparison across changing training periods. It does not establish a head-to-head advantage or show that the two were taken together. Personal report

Doses people discuss

• 70 mg every other day in the blood-test log. The author also reported iron/B12 use. EOD means every other day, not daily and not exactly three times a week. Route and formulation were not explicitly documented in this log; its amount is a self-report, not an authenticated product exposure. Personal report
• 40 mg every three days in the positive two-month account. That commenter did not specify route, formulation or other substances. Every three days is also different from three times weekly. These two amounts must not be presented as the low and high ends of a validated regimen. Personal report
• Three-times-weekly charts came from study extrapolation. In a separate discussion, the author compares 50 mg, 70 mg and roughly 100–120 mg per occasion using research as the rationale. Another commenter derives 50 mg/day from container arithmetic, which the author disputes. The author confirms oral powder use, but neither the arithmetic nor the proposed amounts establishes an optimal cognitive dose. Community · Reddit

Half-life

• The firsthand threads do not establish a bodily half-life. Neither a gap between doses nor a month-to-month blood change measures how quickly roxadustat disappears. The inspected dosing discussion supplies no usable measurement. A clinical half-life is given separately below; it is not a community-measured performance window. Personal report Personal report Community · Reddit

When people first notice a change

• Two-week nonresponse preceded a reported one-month blood change. The same log contains both observations. They describe a blood-test timeline, not the first moment endurance improved. Another person’s favorable report was written after two months of use without saying when the change began. A reliable felt onset remains unknown. Personal report Personal report

How long effects last

• No dependable single-dose felt duration is documented. The favorable reports cover repeated use. The racing-log author later said levels declined somewhat after stopping and moving away from race weight, without a precise interval or follow-up values. That cannot establish how long a benefit persists or when the drug is gone. Personal report Personal report

Courses and breaks

• Plans and completed use are different records. The initial log proposed four more weeks, a short unspecified break and a possible product switch. A later update describes use throughout a racing season without exact dates. The separate positive account covers two months; neither supplies a tested off-period. Personal report Personal report
• Stopping was not always about an adverse effect. The oral-powder discussion author says cost and inconvenience led them to stop. Their proposed reduction after several months is advice extrapolated from research, not a documented successful taper. No standard safe cycle or restart schedule emerges from these threads. Community · Reddit

Cautions that matter

• Blood changes can bring serious risk. The UK product information warns about clots, stroke and potentially life-threatening cardiovascular complications from misuse that raises packed cell volume excessively. A higher hematocrit is not a safety target. Official context
• Blood pressure, potassium and digestive effects matter. EMA lists high blood pressure, high potassium, swelling, diarrhea and nausea among common adverse effects in treated patients. Those clinical frequencies cannot be assumed for healthy self-experimenters. Official context
• Co-use can alter exposure. The label identifies interactions with mineral-containing products, including iron, and with some medicines such as gemfibrozil, probenecid and statins. The log’s iron/B12 co-use cannot establish what exposure occurred. Official context Personal report
• Restrictions depend on the person and formulation. The medicine has pregnancy and breastfeeding restrictions. Evrenzo’s peanut/soya allergy contraindication concerns its ingredients; an unidentified powder has its own unresolved composition. Official context
• Prohibited at all times in WADA-governed sport. Roxadustat is explicitly listed as FG-4592 under HIF activating agents. A forum’s cycle or half-life calculation is not a drug-test clearance window. Official context

What the community record actually shows

• The blood log is one evolving account. SellPrize883 reported unchanged hematocrit and red-cell count at two weeks, then hematocrit moving from 41 to 46.5 after a month. The later post says training, body fat and hydration were similar but admits the effects cannot be isolated. The earlier altitude response is background, not a Roxadustat result. Iron/B12 co-use and unverified products remain relevant. Personal report
• A favorable quotation is not another responder. The later reviews thread repeats Chiefkeef43jvl’s cardio-and-clarity comment. Its own author eventually says they never took roxadustat. Their later praise concerns nicergoline and other changes, so it does not belong in this drug’s benefit record. Community · Reddit Personal report
• A prescribed patient reported benefit in blood tests alongside pain. A person with CKD and a prior kidney transplant described hemoglobin rising from 99 to 123 g/L, then measuring 116 g/L after dose reduction. They reported severe stomach pain and gout-like toe pain while prescribed 20 mg three times weekly. This is a different clinical population; the symptoms were not independently diagnosed or attributed. Personal report
• Neither product appearance nor a null result settles identity. The training-log author first wondered about nonresponse or an inactive product, then said products from two sources seemed similar in taste and appearance. Neither observation authenticates the contents. More exposure, a changed supplier or someone else’s schedule is not an explanation established by this log. Personal report

Clinical timing, kept separate

• About 15 hours is a CKD pharmacokinetic value. The UK label gives an approximately 15-hour mean effective half-life in patients with chronic kidney disease; fasted plasma concentrations usually peak at two hours. These values describe drug concentrations after oral use, not when endurance begins or how long clearer thinking lasts. Official context